Welcome to our dedicated page for Nurix Therapeutics SEC filings (Ticker: NRIX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Nurix Therapeutics, Inc. filings document the regulatory record of a clinical-stage biopharmaceutical company focused on targeted protein degradation medicines. Its 8-K reports furnish quarterly and annual financial results, corporate presentations, clinical-program updates for bexobrutideg and pipeline programs, and other material events tied to research, development and financing activity.
The company’s SEC disclosures also cover its common stock listed on the Nasdaq Global Market, shelf registration and at-the-market equity distribution arrangements, underwritten equity offerings, and use-of-proceeds language tied to clinical development and research programs. Proxy and governance filings document board composition, director appointments, compensation programs, committee assignments and annual stockholder meeting matters.
Nurix Therapeutics, Inc. insider activity: Chief Legal Officer Christine Ring reported option exercises and share sales in Nurix Therapeutics, Inc. common stock. On 01/20/2026, she exercised 3,760 employee stock options at an exercise price of $1.86 per share, acquiring 3,760 shares of common stock. That same day, she sold 3,760 shares of common stock at a weighted average price of $18.4237 per share under a previously adopted Rule 10b5-1 trading plan. After these transactions, she beneficially owned 50,897 shares of common stock directly and 8,643 stock options.
Nurix Therapeutics, Inc. filed a current report to share that it is presenting at the 44th Annual J.P. Morgan Healthcare Conference. On January 12, 2026, the company is providing an overview of its 2025 performance and outlining major goals for 2026 at the event. The associated investor presentation is included as Exhibit 99.1, and a related press release is included as Exhibit 99.2.
The company notes that this conference information is being furnished under Regulation FD and is not deemed filed for liability purposes under the Securities Exchange Act. The filing is primarily informational and centers on disclosure of the materials used at the conference and the accompanying press release.
Nurix Therapeutics, Inc. insider transaction: The company’s Chief Legal Officer, identified as the reporting person, exercised an employee stock option to acquire 3,760 shares of Nurix common stock at an exercise price of $1.86 per share on 12/18/2025. The same day, the insider sold 3,560 shares of common stock at a weighted average price of $17.8661 per share and an additional 200 shares at a weighted average price of $18.555 per share.
These transactions were carried out under a previously adopted Rule 10b5-1 trading plan. After these transactions, the reporting person beneficially owned 50,897 shares of Nurix common stock directly and held 12,403 employee stock options. The option exercised on this date had fully vested by August 9, 2023.
Nurix Therapeutics, Inc. reported an insider equity transaction by its Chief Legal Officer, Christine Ring. On 11/24/2025, she exercised an employee stock option to acquire 37,600 shares of common stock at an exercise price of $1.86 per share, then sold 37,600 shares of common stock on the same date at a weighted average price of $17.0664 per share under a pre-arranged Rule 10b5-1 trading plan. Following these transactions, she beneficially owned 50,897 shares of Nurix common stock directly and 16,163 employee stock options.
Nurix Therapeutics (NRIX) reported a director stock option grant on a Form 4. The filing shows 50,000 options to purchase common stock at an exercise price of $12.52, granted on November 6, 2025, with an expiration date of November 6, 2035.
The option vests as to 1/36 of the total shares monthly beginning December 6, 2025 until fully vested on November 6, 2028, subject to continued service. Ownership is reported as Direct.
Nurix Therapeutics (NRIX) filed a Form 3 reporting the initial beneficial ownership status of director Roger Dansey following an event dated 11/06/2025. The filing states that no securities are beneficially owned. The form was filed by one reporting person and signed by an attorney-in-fact under a Power of Attorney.
Nurix Therapeutics appointed Roger Dansey, M.D. to its Board of Directors and to the Board’s Clinical and Commercialization Committee, effective immediately. He will serve as a Class III director with a term expiring at the company’s 2026 annual meeting of stockholders.
Compensation follows the non-employee director program: a pro rata portion of the $50,000 annual board retainer and a pro rata portion of the $7,500 committee retainer for the remainder of the fiscal year ending November 30, 2025. On November 6, 2025, the Board granted Dr. Dansey an initial stock option for 50,000 shares at the Grant Date closing price, vesting monthly over three years, subject to continued service. He will also be eligible for the customary annual 25,000-share option at each annual meeting, vesting by the next annual meeting or one year, whichever is earlier. Both the Initial Award and each Annual Award accelerate in full upon a Corporate Transaction.
Nurix Therapeutics (NRIX) reported an insider transaction by its Chief Financial Officer. On 11/03/2025, the CFO sold 6,284 shares of common stock in an open-market transaction pursuant to a previously adopted Rule 10b5-1 trading plan.
The sale had a weighted average price of $12.5607, with individual sales ranging from $12.32 to $13.14. Following the transaction, the officer beneficially owns 37,592 shares directly.
Nurix Therapeutics (NRIX) Form 4: Chief Financial Officer Hans van Houte reported RSU-to-share conversions and a tax-related sale on 10/30/2025. Multiple RSU tranches converted to common stock at no cost: 2,886, 2,000, 3,750, and 2,858 shares. To cover withholding taxes tied to these vestings, he executed a mandated “sell-to-cover” of 3,130 shares at a weighted average price of $12.7967.
Following these transactions, he beneficially owned 43,876 shares of common stock directly. The RSUs vest quarterly under existing schedules, and each RSU represents the right to receive one share upon vesting.
Nurix Therapeutics (NRIX) reported insider activity by its Chief Legal Officer, Christine Ring. On 10/30/2025, multiple restricted stock unit (RSU) vestings converted into common stock via code “M” totaling 10,532 shares (1,924; 2,000; 3,750; 2,858), each at $0 per the RSU terms. A subsequent sale of 3,644 shares at a weighted average price of $12.7967 was executed to cover tax withholding obligations under a required “sell-to-cover” arrangement.
Following these transactions, the reporting person held 50,897 shares directly. Each RSU represents a right to receive one share upon vesting, with tranches vesting quarterly pursuant to previously granted awards.